Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAX Baxter International	$23.78 -0.9%	$25.48	$21.33 ▼ $40.49	$12.32B	0.6	5.98 million shs	7.04 million shs
BSX Boston Scientific	$99.75 -2.9%	$104.78	$80.64 ▼ $109.50	$152.19B	0.65	6.38 million shs	12.02 million shs
DXCM DexCom	$75.58 -0.8%	$80.73	$57.52 ▼ $93.25	$29.89B	1.48	4.03 million shs	3.86 million shs
FSNUY Fresenius SE & Co.	$13.91 +1.1%	$12.98	$8.48 ▼ $14.20	N/A	0.82	32,740 shs	56,039 shs
RMD ResMed	$271.39 +0.5%	$274.65	$199.92 ▼ $293.81	$39.55B	0.85	937,685 shs	940,941 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAX Baxter International	-0.92%	-1.23%	-1.74%	-20.52%	-40.13%
BSX Boston Scientific	-2.88%	-7.76%	-3.30%	-1.94%	+19.73%
DXCM DexCom	-0.84%	-3.10%	-6.63%	-7.64%	+8.73%
FSNUY Fresenius SE & Co.	+1.09%	-0.43%	+2.96%	+12.54%	+44.75%
RMD ResMed	+0.27%	-2.86%	-4.72%	+8.50%	+9.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BAX Baxter International	$23.78 -0.9%	$25.48	$21.33 ▼ $40.49	$12.32B	0.6	5.98 million shs	7.04 million shs
BSX Boston Scientific	$99.75 -2.9%	$104.78	$80.64 ▼ $109.50	$152.19B	0.65	6.38 million shs	12.02 million shs
DXCM DexCom	$75.58 -0.8%	$80.73	$57.52 ▼ $93.25	$29.89B	1.48	4.03 million shs	3.86 million shs
FSNUY Fresenius SE & Co.	$13.91 +1.1%	$12.98	$8.48 ▼ $14.20	N/A	0.82	32,740 shs	56,039 shs
RMD ResMed	$271.39 +0.5%	$274.65	$199.92 ▼ $293.81	$39.55B	0.85	937,685 shs	940,941 shs

These 7 Stocks Will Be Magnificent in 2025

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BAX Baxter International	-0.92%	-1.23%	-1.74%	-20.52%	-40.13%
BSX Boston Scientific	-2.88%	-7.76%	-3.30%	-1.94%	+19.73%
DXCM DexCom	-0.84%	-3.10%	-6.63%	-7.64%	+8.73%
FSNUY Fresenius SE & Co.	+1.09%	-0.43%	+2.96%	+12.54%	+44.75%
RMD ResMed	+0.27%	-2.86%	-4.72%	+8.50%	+9.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BAX Baxter International	2.20	Hold	$30.11	26.62% Upside
BSX Boston Scientific	3.08	Buy	$118.04	18.34% Upside
DXCM DexCom	2.91	Moderate Buy	$99.89	32.17% Upside
FSNUY Fresenius SE & Co.	3.33	Buy	N/A	N/A
RMD ResMed	2.82	Moderate Buy	$278.36	2.57% Upside

Current Analyst Ratings Breakdown

Latest BAX, DXCM, RMD, FSNUY, and BSX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2025	BSX Boston Scientific	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$121.00
9/8/2025	BSX Boston Scientific	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$118.00 ➝ $125.00
9/8/2025	DXCM DexCom	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
9/2/2025	RMD ResMed	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Outperform
8/21/2025	DXCM DexCom	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$100.00
8/13/2025	FSNUY Fresenius SE & Co.	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/4/2025	BAX Baxter International	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$41.00 ➝ $36.00
8/4/2025	BAX Baxter International	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$35.00 ➝ $24.00
8/4/2025	BAX Baxter International	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$36.00 ➝ $25.00
8/1/2025	BAX Baxter International	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$33.00 ➝ $24.00
8/1/2025	BAX Baxter International	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$25.00

(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BAX Baxter International	$10.64B	1.15	$4.71 per share	5.05	$13.76 per share	1.73
BSX Boston Scientific	$16.75B	8.83	$3.54 per share	28.14	$14.93 per share	6.68
DXCM DexCom	$4.03B	7.35	$2.23 per share	33.91	$5.38 per share	14.05
FSNUY Fresenius SE & Co.	$23.63B	N/A	$1.30 per share	10.66	$9.83 per share	N/A
RMD ResMed	$5.15B	7.72	$11.26 per share	24.11	$40.70 per share	6.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BAX Baxter International	-$649M	-$0.30	N/A	8.71	0.78	-1.42%	16.96%	5.24%	11/14/2025 (Estimated)
BSX Boston Scientific	$1.85B	$1.68	59.38	30.88	2.47	13.55%	19.21%	10.62%	10/22/2025 (Estimated)
DXCM DexCom	$576.20M	$1.44	52.49	30.72	1.60	13.29%	30.41%	10.08%	10/23/2025 (Estimated)
FSNUY Fresenius SE & Co.	$509.67M	$0.53	26.25	15.12	N/A	5.09%	9.33%	4.31%	11/5/2025 (Estimated)
RMD ResMed	$1.40B	$9.51	28.54	26.20	1.80	27.22%	25.62%	18.69%	10/23/2025 (Estimated)

Latest BAX, DXCM, RMD, FSNUY, and BSX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	FSNUY Fresenius SE & Co.	$0.2182	$0.24	+$0.0218	$0.16	$5.83 billion	$6.48 billion
7/31/2025	Q2 2025	BAX Baxter International	$0.60	$0.59	-$0.01	$0.18	$2.82 billion	$2.81 billion
7/31/2025	Q4 2025	RMD ResMed	$2.47	$2.55	+$0.08	$2.58	$1.33 billion	$1.35 billion
7/30/2025	Q2 2025	DXCM DexCom	$0.45	$0.48	+$0.03	$0.45	$1.13 billion	$1.16 billion
7/23/2025	Q2 2025	BSX Boston Scientific	$0.72	$0.75	+$0.03	$0.53	$4.89 billion	$5.06 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BAX Baxter International	$0.68	2.86%	N/A	N/A	N/A
BSX Boston Scientific	N/A	N/A	N/A	N/A	N/A
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
FSNUY Fresenius SE & Co.	$0.19	1.37%	N/A	35.85%	N/A
RMD ResMed	$2.40	0.88%	N/A	25.24%	13 Years

Latest BAX, DXCM, RMD, FSNUY, and BSX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/14/2025	BAX Baxter International	quarterly	$0.17	2.75%	8/29/2025	8/29/2025	10/1/2025
7/31/2025	RMD ResMed	quarterly	$0.60	0.88%	8/14/2025	8/14/2025	9/18/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BAX Baxter International	1.30	2.30	1.49
BSX Boston Scientific	0.49	1.37	0.82
DXCM DexCom	0.48	1.52	1.35
FSNUY Fresenius SE & Co.	0.49	1.31	1.00
RMD ResMed	0.11	3.44	2.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BAX Baxter International	90.19%
BSX Boston Scientific	89.07%
DXCM DexCom	97.75%
FSNUY Fresenius SE & Co.	N/A
RMD ResMed	54.98%

Insider Ownership

Company	Insider Ownership
BAX Baxter International	0.20%
BSX Boston Scientific	0.50%
DXCM DexCom	0.32%
FSNUY Fresenius SE & Co.	N/A
RMD ResMed	0.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BAX Baxter International	38,000	513.62 million	512.59 million	Optionable
BSX Boston Scientific	53,000	1.48 billion	1.47 billion	Optionable
DXCM DexCom	10,300	392.15 million	390.90 million	Optionable
FSNUY Fresenius SE & Co.	176,486	N/A	N/A	Not Optionable
RMD ResMed	10,600	146.41 million	145.38 million	Optionable

BAX, DXCM, RMD, FSNUY, and BSX Headlines

Recent News About These Companies

Confluence Investment Management LLC Has $29.69 Million Holdings in ResMed Inc. $RMD

September 15 at 6:03 AM | marketbeat.com

Swedbank AB Purchases 324,428 Shares of ResMed Inc. $RMD

September 15 at 5:27 AM | marketbeat.com

AG2R LA Mondiale Gestion D Actifs Makes New $1.55 Million Investment in ResMed Inc. $RMD

September 15 at 4:02 AM | marketbeat.com

ResMed Inc. $RMD Shares Acquired by Intech Investment Management LLC

September 15 at 3:19 AM | marketbeat.com

Inspire Investing LLC Boosts Holdings in ResMed Inc. $RMD

September 14 at 5:48 AM | marketbeat.com

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Buys 22,789 Shares of ResMed Inc. $RMD

September 14 at 4:19 AM | marketbeat.com

MBB Public Markets I LLC Invests $302,000 in ResMed Inc. $RMD

September 14 at 4:10 AM | marketbeat.com

WBI Investments LLC Trims Position in ResMed Inc. $RMD

September 13 at 5:46 AM | marketbeat.com

Goldman Sachs Group Inc. Grows Stock Position in ResMed Inc. $RMD

September 13 at 3:59 AM | marketbeat.com

ResMed (NYSE:RMD) Shares Down 4.7% - Time to Sell?

September 12, 2025 | marketbeat.com

Here's Why ResMed (RMD) is a Strong Growth Stock

September 12, 2025 | zacks.com

38,139 Shares in ResMed Inc. $RMD Bought by Capital Impact Advisors LLC

September 12, 2025 | marketbeat.com

ResMed Inc. $RMD Shares Sold by Zurich Insurance Group Ltd FI

September 12, 2025 | marketbeat.com

ImmuCell (NASDAQ:ICCC) & ResMed (NYSE:RMD) Critical Comparison

September 12, 2025 | americanbankingnews.com

United Services Automobile Association Buys New Stake in ResMed Inc. $RMD

September 11, 2025 | marketbeat.com

1,144 Shares in ResMed Inc. $RMD Purchased by Petrus Trust Company LTA

September 11, 2025 | marketbeat.com

PharVision Advisers LLC Buys New Shares in ResMed Inc. $RMD

September 9, 2025 | marketbeat.com

Alliancebernstein L.P. Cuts Position in ResMed Inc. $RMD

September 9, 2025 | marketbeat.com

Adage Capital Partners GP L.L.C. Sells 21,876 Shares of ResMed Inc. $RMD

September 9, 2025 | marketbeat.com

The sleep economy is 'having a moment', says medical equipment firm Resmed

September 8, 2025 | youtube.comY

Parkman Healthcare Partners LLC Takes $5.06 Million Position in ResMed Inc. $RMD

September 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BAX, DXCM, RMD, FSNUY, and BSX Company Descriptions

Baxter International NYSE:BAX

$23.78 -0.21 (-0.88%)

Closing price 09/15/2025 03:59 PM Eastern

Extended Trading

$23.88 +0.09 (+0.40%)

As of 09/15/2025 07:54 PM Eastern

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Boston Scientific NYSE:BSX

$99.75 -2.96 (-2.88%)

Closing price 09/15/2025 03:59 PM Eastern

Extended Trading

$100.50 +0.75 (+0.75%)

As of 09/15/2025 07:57 PM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

DexCom NASDAQ:DXCM

$75.58 -0.64 (-0.84%)

Closing price 09/15/2025 04:00 PM Eastern

Extended Trading

$75.58 +0.00 (+0.01%)

As of 09/15/2025 07:48 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Fresenius SE & Co. OTCMKTS:FSNUY

$13.91 +0.15 (+1.09%)

As of 09/15/2025 03:51 PM Eastern

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

ResMed NYSE:RMD

$271.39 +1.25 (+0.46%)

Closing price 09/15/2025 03:59 PM Eastern

Extended Trading

$278.00 +6.61 (+2.44%)

As of 09/15/2025 07:59 PM Eastern

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BAX, DXCM, RMD, FSNUY, and BSX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BAX, DXCM, RMD, FSNUY, and BSX Earnings

Compare Dividends

Latest BAX, DXCM, RMD, FSNUY, and BSX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BAX, DXCM, RMD, FSNUY, and BSX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BAX, DXCM, RMD, FSNUY, and BSX Company Descriptions

Baxter International NYSE:BAX

Boston Scientific NYSE:BSX

DexCom NASDAQ:DXCM

Fresenius SE & Co. OTCMKTS:FSNUY

ResMed NYSE:RMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools